Caris & Company Downgrades Endo Pharmaceuticals (ENDP) to Above Average
More News related to ENDP
- Endo Pharma (ENDP) Announces Settlement with LecTec Over Outstanding Patent Litigation
- Endo Pharmaceuticals and LecTec Settle Patent Dispute
- Endo Pharma (ENDP) Posts Q3 EPS of $0.63, Misses By 1c; Guides
- Endo Pharmaceuticals Reports Third Quarter 2009 Financial Results and Increases Full-Year Financial Guidance
- Trading Radar for 10/29: Exxon (XOM), Motorola (MOT), Waste Management (WM) Report
More News related to Downgrades
- Shields & Co. Downgrades ALLETE, Inc. (ALE) to Hold
- Scotia Capital Downgrades Grupo Aeroportuario del Centro (OMAB) to Sector Perform
- Goldman Sachs Upgrades Bradesco and Banco do Brasil; Downgrades Bancolombia
- Wedbush Downgrades Burger King (BKC) to Underperform
- Morgan Stanley Upgrades Safeway (SWY), Downgrades SUPERVALU (SVU)
Caris & Company downgrades Endo Pharmaceuticals Holdings Inc. (Nasdaq: ENDP) from Buy to Above Average with a $28 price target.
Endo Pharmaceuticals Holdings, Inc. engages in the research, development, sale, and marketing of branded and generic prescription pharmaceuticals for treating and managing pain.
Related Categories
DowngradesStocks Mentioned
-0.57Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
